Related Experiment Video
Updated: Apr 13, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis
Shuangnian Xu1, Xi Li, Jianmin Zhang
1Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Insights
CD56 overexpression is linked to poorer outcomes in acute myeloid leukemia (AML). This meta-analysis confirms CD56 as a potential adverse prognostic factor, impacting overall survival and disease-free survival in AML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- The prognostic significance of CD56 in acute myeloid leukemia (AML) has been extensively studied, yet findings remain inconsistent.
- Clarifying the role of CD56 is crucial for refining AML patient risk stratification and treatment strategies.
Purpose of the Study:
- To conduct a meta-analysis to definitively assess the prognostic value of CD56 in patients with acute myeloid leukemia (AML).
- To resolve existing controversies regarding the association between CD56 expression and clinical outcomes in AML.
Main Methods:
- A systematic literature search was performed across major databases (PubMed, Embase, Cochrane Library, CBM).
- Studies evaluating CD56 prognostic value in AML patients were included.
- Pooled hazard ratios (HRs) for overall survival (OS) and disease-free survival (DFS), and pooled odds ratios (ORs) for complete remission rate (CRR) and relapse rate (RR) were calculated.
Main Results:
- The meta-analysis included 32 studies encompassing 4074 patients.
- CD56 overexpression was associated with shorter OS and DFS, and increased relapse rates (RR) in AML overall, and specifically in AML with t(8;21) and t(15;17) translocations.
- CD56 overexpression was also linked to decreased complete remission rates (CRR) in AML with t(15;17) and AML overall.
Conclusions:
- CD56 overexpression emerges as a significant adverse prognostic factor in acute myeloid leukemia (AML).
- These findings support the utility of CD56 as a biomarker for predicting outcomes in AML patients.
Purpose:
Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.
Methods:
A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.
Results:
Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30-3.78) and DFS (HR 2.63; 95 % CI 1.10-6.29) and increased RR (OR 3.29; 95 % CI 1.67-6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49-1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66-3.57) and DFS (HR 4.27; 95 % CI 1.15-15.78), increased RR (OR 3.11; 95 % CI 2.01-4.81), and decreased CRR (OR 0.42; 95 % CI 0.25-0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38-2.19) and DFS (HR 2.38; 95 % CI 1.87-3.02), increased RR (OR 5.19; 95 % CI 2.84-9.48), and decreased CRR (OR 0.62; 95 % CI 0.41-0.96).
Conclusions:
This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018